Company Active LTD

Company profile

Aglaris Limited

UK company 09111674, incorporated on 2 July 2014.

Aglaris

Aglaris Limited is a UK company with status Active founded in 2014.

Company number
09111674
Incorporated
2 Jul 2014
Companies House status
Active

Company identity

Founded / incorporated
2 July 2014

Company number 09111674

Verify at Companies House
Legal name
AGLARIS LIMITED
Company type
Private Limited Company
Region
Unknown
Registered address
167-169 GREAT PORTLAND STREET GREAT PORTLAND STREET
5TH FLOOR
LONDON
ENGLAND
W1W 5PF
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

30 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

16 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

02 Jul
2014

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2018
Funded years
2018, 2020
Age at first award
3 years

Projects

2020 Collaborative R&D Lead participant

Development of transduction process in cell culture platform

13 Jul 2020 to 13 Jul 2021

Awarded
£724,476
Total cost £982,869

Development of transduction process in cell culture platform

2018 EU-Funded Lead participant

Thermoresponsive Microcarriers for Mesenchymal Stem Cells Cultures

1 Oct 2018 to 31 May 2021

Awarded
£250,617
Total cost £417,696

Awaiting Public Project Summary

2018 Collaborative R&D Lead participant

Improving T-Cell manufacture through automation - scaling out, reducing costs and increasing quality to meet the emerging demand for patient-tailored cancer therapies.

1 Jul 2018 to 30 Sep 2019

Awarded
£338,053
Total cost £482,932

"**Objective:** Improve scalability, quality, costs, flexibility and efficiency of T cell manufacturing by developing and integrating novel processes and manufacturing technologies. **Need or Challenges**: While T cells have been shown to produce game-changing results by curing previously untreatable cancers in numerous clinical trials, the T-cell manufac...

Product types

Collaborative R&D EU-Funded